Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
To demonstrate the bioequivalence of saxagliptin and metformin in a saxagliptin,
5-mg/metformin extended-release (XR), 500-mg, fixed-dose combination (FDC) tablet with
saxagliptin, 5-mg and metformin, 500-mg XR tablets administered together in both the fasted
and fed states. In addition, to demonstrate the bioequivalence of saxagliptin and metformin
in a saxagliptin, 5-mg/metformin XR, 1000-mg, FDC tablet with saxagliptin, 5-mg and
metformin, 1000-mg XR tablets administered together in both the fasted and fed states.